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Objective. To present an institution’s 2-year experience of non-myeloablative
allogeneic stem cell transplantation among Chinese patients.
Design. Retrospective study.
Setting. Bone marrow transplantation unit at a university hospital, Hong Kong.
Patients. Ten patients with multiple myeloma who received non-myeloablative
allogeneic stem cell transplantation between March 2000 and October 2002.
Intervention. Fludarabine (90 mg/m2) and total body irradiation (300 cGy) were
given as conditioning regimens, followed by non-myeloablative allogeneic stem
cell transplantation.
Main outcome measures. Engraftment, regimen-related toxicity, treatment-related
mortality (in the first 100 days), incidence of graft-versus-host disease, chimerism,
disease response, and survival rate.
Results. All 10 patients had active disease before transplantation. The donors were
eight human leukocyte antigen–matched siblings, a mismatched sibling, and a
matched daughter. Satisfactory engraftment before day 21 was achieved without
early treatment-related mortality. Five patients developed full donor chimerism by
day 28 and three other patients had 100% donor chimerism by day 100. Acute
graft-versus-host disease developed in six patients (five with grade III and one
with grade IV disease), and chronic graft-versus-host disease developed in eight
patients (four with extensive disease). Complete remission and partial response
were achieved in three and four patients, respectively. Three patients did not respond
to treatment, and one case of relapse was observed. Only one patient, who had
shown a partial response, received donor lymphocyte infusion; seven patients
received thalidomide for graft-versus-host disease with or without graft-versus-
myeloma effect. All patients were alive after a median follow-up of 1 year.
Conclusion. Non-myeloablative allogeneic stem cell transplantation for multiple
myeloma is effective, has low toxicity, and results in low treatment-related mortality.
Studies of more cases with longer follow-up durations are required.
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Introduction
Multiple myeloma is a malignant disorder of plasma cells.
The disease is common in the elderly population; the median
age at diagnosis is 65 years and the median survival time
associated with conventional therapy is 3 years or less.1
Multiple myeloma is incurable, however, and the complete
remission rate and 10-year survival are less than 5%.2
Autologous bone marrow transplantation (ABMT) has been
used increasingly during the past 15 years and achieves a
treatment-related mortality of less than 5% and a durable
complete remission rate of 30% to 50% among newly
diagnosed patients.3 Two prospective randomised controlled
trials and three other studies with historical comparisons
have shown that ABMT is superior to conventional
chemotherapy in terms of complete remission rate and event-
free survival. However, the better overall survival attributed
to ABMT was not substantiated in all studies and, more
importantly, the survival curve did not reach a plateau,
implying that this modality may not be curative and that
factors such as conditioning regimen and optimal timing of
ABMT still need to be improved.4-7
The role of allogeneic stem cell transplantation (allo-
SCT) remains controversial in the management of multiple
myeloma.8,9 The European Group for Blood and Marrow
Transplantation has shown no overall survival benefit of
allo-SCT over ABMT,10 because the treatment-related
mortality after allo-SCT in the first 100 days is as high
as 30% to 50%—mostly as a result of the old age of the
patients, intensive chemotherapy before transplantation,
and co-morbidity.11,12 Still, about 40% of patients with
complete remission can remain disease-free for 6 years
and longer.10,12 The graft-versus-myeloma (GVM)
effect probably makes allo-SCT the only curative
therapy for multiple myeloma.10,13-15 Furthermore, donor
lymphocyte infusion for relapse after allo-SCT gives
satisfactory results.16,17 The benefit of allo-SCT, however,
is hampered by the high incidence of graft-versus-host
disease (GVHD).16,18
In the past 5 years, the use of non-myeloablative con-
ditioning regimens followed by stem cell infusion has been
shown to achieve stable engraftment in various hae-
matological malignancies.19-24 Badros et al25,26 found that
non-myeloablative conditioning regimens based on
melphalan 100 mg/m2 in heavily pre-treated high-risk
patients with multiple myeloma were well-tolerated; the
protocol led to a lower treatment-related mortality and
satisfactory donor engraftment. However, relevant data
have not yet been documented for Chinese patients. In this
article, we present our experience of non-myeloablative
allo-SCT with fludarabine and total body irradiation as the
conditioning regimen among 10 Chinese patients.
Patients and methods
Study design
From March 2000 to October 2002, 10 Chinese patients with
multiple myeloma underwent non-myeloablative peripheral
blood stem cell (PBSC) transplantation in the Bone Marrow
Transplantation Unit of the Queen Mary Hospital. All
patients had not achieved a complete response after
chemotherapy, but suitable human leukocyte antigen
(HLA)–matched donors were available. Written consent was
obtained from both donors and recipients. The conditioning
regimens consisted of intravenous fludarabine (30 mg/m2)
from day 5 to day 3 and total body irradiation (150 cGy) on
days 2 and 1.
Prophylaxis for GVHD consisted of oral mycopheno-
late mofetil (15 mg/kg) twice daily from day 0 to 28
and intravenous cyclosporin, starting at a dosage of
1.2 mg.kg-1.d-1 on day 1 (adjusted to a target serum level
concentration of 250-300 ng/µL). Treatment was switched
to oral cyclosporin if the drug was tolerated. Methotrexate
was not included in the GVHD prophylaxis regimen.
Cyclosporin was tapered gradually after day 60 in the
absence of GVHD.
Bone marrow examination, serum immunoglobulin
electrophoresis, and immunofixation were performed on
day 28 and repeated at 3, 6, 12, 18, and 24 months to assess
the disease status. Patients with persistent, progressive,
or relapsed disease had immunosuppression discontinued
in the absence of GVHD. If there was evidence of disease
progression, donor lymphocyte infusion with or without
oral thalidomide starting at 100 mg/d were administered.
Antimicrobial prophylaxis during the transplant period
consisted of oral acyclovir 200 mg three times daily from
day 0 to day 30 and oral fluconazole 200 mg/d and oral
ciprofloxacin 500 mg two times daily from day 6 to day 30.
Pentamidine inhalation 300 mg once every 3 weeks was
also given and then switched to oral co-trimoxazole 960 mg
two times per week if the neutrophil count recovered within
1 year. Polymerase chain reaction (PCR) analysis was used
to check for cytomegalovirus (CMV) weekly in the first 100
days and then monthly until 1 year. Patients who were CMV-
positive were tested for CMV pp65 antigenaemia and treated
with ganciclovir (5 mg/kg) three times per week. In
refractory cases, foscarnet (60 mg.kg-1.d-1) was administered.
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On days 0 and 1, patients received an allogeneic PBSC
graft from their HLA-matched donor that had been activated
with granulocyte colony-stimulating factor (G-CSF).
Subcutaneous G-CSF 10 µg.kg-1.d-1 had been given to the
donor for 4 days and leukopheresis (>15 L) was performed
on the fourth and fifth day. The target stem cell count
was more than 1 x 106 CD34-bearing cells per kg of the
patient’s weight. Stem cells were not manipulated and were
cryopreserved.
Study end-point
Engraftment, regimen-related toxicity, treatment-related
mortality (in the first 100 days), acute GVHD incidence,
and chimerism were the primary end-points of this study.
Secondary end-points included disease response, survival
rate, and chronic GVHD incidence. Acute GVHD was
assessed according to the scale suggested by Glucksberg
et al,27 and chronic GVHD was defined as GVHD that
occurred after 100 days and was graded as none, limited, or
extensive.28 Other toxicities were assessed using the United
States National Cancer Institute criteria. Engraftment was
defined as a neutrophil count of more than 0.5 x 109 /L for 3
consecutive days and an untransfused platelet count
exceeding 20 x 109 /L. The degree of donor-recipient
chimerism was assessed by performing a PCR assay of the
short tandem repeats in the relevant locus according to
published methods.29 Chimerism was assessed on days
28 and 100 and thereafter when clinically indicated. The
presence of more than 5% donor or recipient cells in the
sample was defined as mixed chimerism (the assay is
sensitive to detect chimerism if more than 5% donor DNA
is present).
Complete remission was assumed to have occurred
when monoclonal paraprotein in the serum and urine
was undetectable for a minimum of 6 weeks by serum
immunoglobulin electrophoresis and immunofixation,
and when the bone marrow aspirate contained less than 5%
of plasma cells. Complete remission with only positive
immunofixation was defined as near-complete remission.
A partial response was defined as a reduction in disease
burden by more than 50%. Relapse implied a recurrence of
monoclonal protein or bone marrow plasmacytosis in
patients who had achieved complete remission. A patient
was assumed to show no response if there was no change in
the disease status. Progression was when the disease
progressed in a patient who had previously shown partial
remission or no response.
Results
Baseline characteristics of the study patients are shown in
Table 1. The median age of the 10 patients (six men and
four women) with multiple myeloma who received non-
myeloablative PBSC transplantation was 51 years (range,
42-62 years). All patients presented at disease stage III (Durie
and Salmon) at diagnosis and had been treated with
chemotherapy only. The median number of chemotherapy
regimens was 6.5. Only one patient had previously received
an ABMT. Five patients had shown a partial response and
five patients no response after chemotherapy at the time
of transplant. Eight patients received a graft from
HLA-matched siblings, one received a graft from her
HLA-matched daughter, and the remaining patient received a
HLA class-II (DR) antigen-mismatched graft from his sibling.
Clinical response, engraftment, and chimerism
A median of 1.84 x 106 CD34-positive cells per kg (range,
0.85-3.74 x 106) and 7.51 x 106 colony-forming unit–
granulocyte-monocyte per kg (range, 0.95-23.00 x 106)
were given to the patients. The median day for the onset
of neutropenia was day 6 (range, 4-9) and the median day
of engraftment was day 19 (range, 11-23). No patient
required platelet transfusion. The lowest platelet count
was 29 x 109 /L, and three of the 10 patients had a lowest
platelet count of more than 100 x 109 /L. Six patients required
a transfusion of red blood cells (four required 2 units and
two required 4 units) and three patients required G-CSF
after transplantation. Three patients had major ABO
incompatibilities and there was no delayed engraftment or
increased requirement for red blood cell transfusion in the
first 100 days among these three patients. On day 28, half
of the 10 patients had full donor chimerism and three other
patients had full chimerism on day 100. Hence, eight
patients displayed full chimerism and two had mixed
chimerism (of 60% and 96%) on day 100 (Table 2).
The best responses of the bone marrow plasma cell
and serum paraprotein after bone marrow transplantation
are shown in Table 3. Three patients showed a complete
response with undetectable paraprotein at 6 months, but
one of them had a relapse at 1 year. Four patients had a
partial response at a median follow-up of 1 year, and two of
them subsequently showed disease progression. No
extramedullary disease was recorded. Three patients
displayed no response, with a follow-up period of 1 year in
one patient and 4 months for the remaining two patients.
Seven of the 10 patients received thalidomide for either
GVHD treatment or augmented GVM effect, because the
drug has been shown to be effective in these situations.30,31
Only one patient, who had shown a partial response to
treatment, had donor lymphocyte infusion at 6 months of
follow-up for disease progression; no extensive GVHD
was observed in this patient after infusion.
Overall survival, toxicity, and mortality
During follow-up (range, 80-960 days; median, 400 days),
there were no patient deaths. The major regimen-related
toxicity was GVHD. Six patients had acute GVHD: five
with grade III and one with grade IV. The latter patient had
received an HLA-mismatched graft from her sibling and
developed grade-IV GVHD with a clinical picture of toxic
epidermal necrosis; she was treated with anti-thymocyte
globulin, mycophenolate mofetil, cyclosporin, steroid, and
thalidomide. The skin GVHD in this patient recovered but
she subsequently developed extensive chronic GVHD
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involving the liver and lung (bronchiolitis obliterans). Four
patients had extensive chronic GVHD (two with complete
remission and two with a partial response) and four had
limited GVHD. In contrast, two of the three patients who
showed no response had limited chronic GVHD only. The
third patient who had displayed complete remission did not
have chronic GVHD but relapsed subsequently. Five months
after transplantation, one of the three patients with complete
.oNtneitaP lihportuenfonoitaruD
*)syad(tnemtfargne
fonoitaruD
)syad(aineportuen
llecdoolbdeR
)stinu(noisufsnart
-ynolocetycolunarG
desurotcafgnitalumits
msiremihcronoD
)%(001yad/82yad
11
12
13
14
15
16
17
18
19
01
12
71
22
12
81
11
02
32
91
81
6
5
6
5
6
9
8
6
4
7
4
0
2
4
0
0
2
0
2
2
oN
oN
seY
oN
seY
oN
oN
oN
oN
seY
001/001
1 001/57
1 001/69
1 001/29
1 06/98 0
1 69/88 0
001/001
001/001
001/001
001/001
Table 2.  Clinical course and outcome after stem cell transplantation
* No. of days to achieve an absolute neutrophil count of >0.5 x 109 /L
† Since first day when neutrophil count was <0.5 x 109 /L
‡ Numbers in parentheses indicate the grading of acute graft-versus-host disease
§ aGVHD        acute graft-versus-host disease
|| Treated with anti-thymocyte globulin, mycophenolate mofetil, cyclosporin, steroid, and thalidomide
†
.oNtneitaP xes/)sraey(egA egas’ronoD
xes/)sraey( g
s’ronoD
pihsnoitaler
etycokuelnamuH
gnihctamnegitna
nietorparaP
epytbus
taegatS
*noitatneserp
11
12
13
14
15
16
17
18
19
01
M/25
M/65
M/05
M/24
M/74
F/75
M/05
F/84
F/26
F/65
M/64
F/65
M/05
M/73
F/94
M/55
F/73
M/53
M/76
F/92
gnilbiS
gnilbiS
gnilbiS
gnilbiS
gnilbiS
gnilbiS
gnilbiS
gnilbiS
gnilbiS
rethguaD
lluF
lluF
lluF
lluF
lluF
lluF
lluF
negitnaroniM
hctamsim
lluF
lluF
appaK/G
adbmaL/A
appaK/G
ateB/A
adbmaL/A
adbmaL/G
adbmaL/D
appaK/G
appaK/G
adbmaL/G
AIII
BIII
AIII
AIII
AIII
AIII
BIII
AIII
AIII
AIII
Table 1.  Baseline characteristics of the 10 patients undergoing non-myeloablative peripheral blood stem cell transplantation
* Durie and Salmon staging
† Reference level, <1.5 µg/mL
‡ VAD vincristine/adriamycin/dexamethasone
§ VCMP vincristine/cyclophosphamide/melphalan/prednisolone
|| MP melphalan/prednisolone
tneitaP
.oN
)%(levelllecamsalpworramenoB )L/g(levelnietorparapmureS
noitatnalpsnart-erP *noitatnalpsnart-tsoP noitatnalpsnart-erP *noitatnalpsnart-tsoP egnahC tsebotemiT
)shtnom(esnopser
11
12
13
14
15
16
17
18
19
01
> 01
> 12
> 32
> 61
> 01
> 51
05>
> 01
05>
> 83
> 21
0> 2
0> 2
0> 1
> 01
0> 1
0> 2
0> 1
05>
> 82
12 5.
42 5.
5.03
43 5.
ecarT
62 5.
ecarT
4.41
04 5.
2.15
7.5
9.
2 8.3
0.
21 7..
7.2 0.
0.
6.7
5.35
4.63
%27-
%26-
%78-
%001-
A/N
%001-
A/N
%74-
%33+
%82-
81
42
21
26
26
26
23
23
23
23
* Values are at best response
† % change compared with pre-transplantation value
‡ Positive immunofixation only
§ Patients 9 and 10 had 4 months of follow-up only
|| N/A        not applicable
Table 3.  Paraprotein and bone marrow response
§
§
‡
‡
||
†
Donor’r’s age
Hong Kong Med J Vol 10 No 2 April 2004     81
Stem cell transplantation for multiple myeloma
remission had carcinoma of the stomach, which was treated
with gastrectomy (Table 2). No cases of severe septicaemia
or fungal infection were documented. Seven patients had
CMV reactivation that were detectable by PCR analysis and
all of them and their donors were CMV antibody–positive.
Four of these seven patients were treated with ganciclovir
alone and three received both ganciclovir and foscarnet.
None of the patients developed clinical CMV disease.
Discussion
Multiple myeloma is common in the elderly age-group
and is considered incurable using chemotherapy alone.
Although traditional allo-SCT can result in a 50% complete
remission rate at 6 years, the unacceptably high early
treatment-related mortality (30%-50%) makes its application
very limited.10-12 The emergence of non-myeloablative
PBSC (known as mini-PBSC) transplantation offers new
hope to patients with multiple myeloma, especially to those
who may have co-morbidities and those who have been
heavily treated with chemotherapy, thereby rendering them
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unsuitable for conventional allo-SCT. Some reports have
shown that mini-PBSC for multiple myeloma can achieve
satisfactory engraftment and much lower early treatment-
related mortality.25,26
Half of the patients in our series achieved full donor
chimerism before day 28, and three other patients had full
donor chimerism by day 100; thus, 80% of patients
developed full chimerism. Sequential donor lymphocyte
infusion was omitted because of the high incidence of
GVHD after infusion in this setting.25,26 Only one of the
patients received donor lymphocyte infusion at 6 months
because of progressive disease. The overall incidence of
acute GVHD (60%) is comparable to that associated with
conventional allo-SCT. However, the fact that all acute
GVHD cases were grade III or above is of great concern.
Our short course of mycophenolate mofetil for GVHD
prophylaxis (from day 0 to day 28 only) may be insufficient
because of the more severe acute GVHD: extensive
debilitating chronic GVHD developed in four patients.
Yet, the follow-up duration is relatively short and the true
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chronic GVHD incidence is expected to be higher. The
phenomenon of delayed engraftment resulting from ABO-
incompatibility is still controversial.32,33 In our study, the
three ABO-incompatible recipients did not experience a
delay in engraftment. A decreased requirement for
transfusion was reported in patients receiving non-
myeloablative transplantation when compared with those
receiving conventional allo-SCT.34 This phenomenon
was also observed in our patients: none required platelet
transfusion and only six of the 10 patients required a
transfusion of red blood cells.
Seventy percent of the patients in our series achieved
at least a partial response to mini-PBSC, and 30% achieved
complete remission. Extensive chronic GVHD occurred
only in patients displaying a partial response or complete
remission; in contrast, all patients who showed no response
to treatment had limited GVHD. Only one patient, who had
shown complete remission, relapsed in the absence of
chronic GVHD. A GVM effect must be responsible for
this observation. Although the effect of GVM of pre-emptive
donor lymphocyte infusion is appealing,16,17,35 the high
incidence of GVHD has limited its application.
Fludarabine combined with total body irradiation in our
study resulted in successful engraftment before day 28 for
all patients. There was no early treatment-related mortality
and at a short median follow-up duration of about 1 year,
all patients were still alive. Although there was no severe
sepsis or fungal infection, the CMV reactivation rate in the
early 6 months (70%) was high, and comparable to the rate
documented in the literature.36 No CMV disease was
documented, however. All cases of CMV reactivation were
responsive to ganciclovir alone or in combination with
foscarnet. Such high CMV reactivation rate may be related
to the delayed recovery of the CD3 and CD4 counts in the
first 6 months.26
One of the drawbacks of this study is the lack of docu-
mentation of immune reconstitution by CD3 and CD4
count analysis; consequently, the relationship between
immune reconstitution and events such as GVHD and CMV
reactivation cannot be established. Despite the small
number of patients and short follow-up period, we have
shown that mini-PBSC using fludarabine and total body
irradiation as a conditioning protocol is safe and effective.
Studying more cases and increasing the follow-up duration
are required to demonstrate the real benefit of this treatment
in overall survival and long-term disease control. Moreover,
issues such as optimal conditioning regimens, GVHD
prophylaxis, and timing of transplantation need to be
addressed by further studies.
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